SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : VD's Model Portfolio & Discussion Thread
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: sim1 who wrote (7147)10/13/1999 4:00:00 PM
From: biowa  Read Replies (1) of 9719
 
Stuart,

WOW!! If the stock reacts like this to news on a canine model, what will it do with a first approval in South Africa or good results in the US PIII?

Actually, this has long been one of the strengths of these "molecular oxygenators," that has led to the "blood substitutes" evolving into the term "oxygen therapeutics." Because of the relatively small size of the molecules (as compared to a red blood cell), they can efficiently carry oxygen past blockages that RBCs can't. There are opportunities for this in cardiac surgery (as this demonstrates), chemo/radiotherapy, perhaps ischemic stroke, etc.

Of course, one of the criticisms of other hemoglobin-based candidates has been that the small size reduces the half-life, leads to leakage out of the circulation, etc. I don't believe that such problems have been seen with Hemopure.

Thanks for the link,
biowa
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News